ACADIA Pharmaceuticals Statistics
Total Valuation
ACAD has a market cap or net worth of $2.80 billion. The enterprise value is $2.40 billion.
| Market Cap | 2.80B |
| Enterprise Value | 2.40B |
Important Dates
The next estimated earnings date is Monday, May 6, 2024, after market close.
| Earnings Date | May 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ACAD has 164.77 million shares outstanding. The number of shares has increased by 1.32% in one year.
| Shares Outstanding | 164.77M |
| Shares Change (YoY) | +1.32% |
| Shares Change (QoQ) | +0.35% |
| Owned by Insiders (%) | 0.49% |
| Owned by Institutions (%) | 99.51% |
| Float | 109.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 25.29 |
| PS Ratio | 3.85 |
| Forward PS | 2.84 |
| PB Ratio | 6.48 |
| P/FCF Ratio | 168.12 |
| PEG Ratio | -0.42 |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.31 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 144.29 |
Financial Position
The company has a current ratio of 2.42, with a Debt / Equity ratio of 0.11.
| Current Ratio | 2.42 |
| Quick Ratio | 2.15 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | 2.87 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -15.70% and return on invested capital (ROIC) is -15.30%.
| Return on Equity (ROE) | -15.70% |
| Return on Assets (ROA) | -9.10% |
| Return on Capital (ROIC) | -15.30% |
| Revenue Per Employee | $1.21M |
| Profits Per Employee | -$102,485 |
| Employee Count | 598 |
| Asset Turnover | 1.08 |
| Inventory Turnover | 1.60 |
Taxes
In the past 12 months, ACAD has paid $10.25 million in taxes.
| Income Tax | 10.25M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.64% in the last 52 weeks. The beta is 0.39, so ACAD's price volatility has been lower than the market average.
| Beta (1Y) | 0.39 |
| 52-Week Price Change | -15.64% |
| 50-Day Moving Average | 20.83 |
| 200-Day Moving Average | 24.68 |
| Relative Strength Index (RSI) | 31.08 |
| Average Volume (30 Days) | 1,814,777 |
Short Selling Information
The latest short interest is 11.20 million, so 6.80% of the outstanding shares have been sold short.
| Short Interest | 11.20M |
| Short Previous Month | 10.63M |
| Short % of Shares Out | 6.80% |
| Short % of Float | 10.19% |
| Short Ratio (days to cover) | 4.66 |
Income Statement
In the last 12 months, ACAD had revenue of $726.44 million and -$61.29 million in losses. Loss per share was -$0.37.
| Revenue | 726.44M |
| Gross Profit | 684.80M |
| Operating Income | -73.38M |
| Pretax Income | -51.04M |
| Net Income | -61.29M |
| EBITDA | -45.48M |
| EBIT | -51.04M |
| Loss Per Share | -$0.37 |
Balance Sheet
The company has $444.64 million in cash and $47.80 million in debt, giving a net cash position of $396.84 million or $2.41 per share.
| Cash & Cash Equivalents | 444.64M |
| Total Debt | 47.80M |
| Net Cash | 396.84M |
| Net Cash Per Share | $2.41 |
| Equity / Book Value | 431.76M |
| Book Value Per Share | 2.62 |
| Working Capital | 361.87M |
Cash Flow
In the last 12 months, operating cash flow was $16.70 million and capital expenditures -$50,000, giving a free cash flow of $16.65 million.
| Operating Cash Flow | 16.70M |
| Capital Expenditures | -50,000 |
| Free Cash Flow | 16.65M |
| FCF Per Share | $0.10 |
Margins
Gross margin is 94.27%, with operating and profit margins of -10.10% and -8.44%.
| Gross Margin | 94.27% |
| Operating Margin | -10.10% |
| Pretax Margin | -7.03% |
| Profit Margin | -8.44% |
| EBITDA Margin | -6.26% |
| EBIT Margin | -7.03% |
| FCF Margin | 2.29% |
Dividends & Yields
ACAD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.32% |
| Shareholder Yield | -1.32% |
| Earnings Yield | -2.19% |
| FCF Yield | 0.59% |
Analyst Forecast
The average price target for ACAD is $30.90, which is 81.87% higher than the current price. The consensus rating is "Buy".
| Price Target | $30.90 |
| Price Target Difference | 81.87% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
| Revenue Growth Forecast (5Y) | 19.70% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ACAD has an Altman Z-Score of 2.08 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.08 |
| Piotroski F-Score | 4 |